Advertisement

Gastric Cancer

  • Koshi KumagaiEmail author
  • Takeshi Sano
Chapter

Abstract

Lymph node metastasis is the most important prognostic factor in potentially curable gastric cancer. Since 2010 the TNM classifications and the Japanese classification have been harmonized in terms of the N-category determined with the number of metastatic lymph nodes and of the stage grouping.

The D-number to describe the extent of lymph node dissection in gastrectomy is used to be defined in accordance with lymph node groups based on the primary tumor location. In the third edition of the Japanese guidelines published in 2010, the lymph node stations to be dissected in D1, D1+, and D2 were newly defined for total or distal gastrectomy regardless of the tumor location.

The 15-year follow-up of the Dutch trial demonstrated that the locoregional recurrence rate was significantly lower in patients treated with D2 than D1, showing a survival benefit. Today the D2 procedure has been recommended in most guidelines for patients with resectable advanced gastric cancer. There are debates on an optimal extent of lymph node dissection in esophagogastric junction cancer or cancer with duodenal invasion.

Keywords

Gastric cancer Lymph node metastasis Therapeutic value index Classification Guidelines 

References

  1. 1.
    Hermanek P, Sobin LH. International union against cancer: TNM classification of malignant tumours. 4th fully revised ed. Berlin: Springer-Verlag; 1987.Google Scholar
  2. 2.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer. 1998;1:10–24.CrossRefGoogle Scholar
  3. 3.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.CrossRefGoogle Scholar
  4. 4.
    Ichikura T, Tomimatsu S, Okusa Y, Uefuji K, Tamakuma S. Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer. J Clin Oncol. 1993;11(10):1894–900.CrossRefGoogle Scholar
  5. 5.
    Wu CW, Hsieh MC, Lo SS, et al. Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. Gut. 1996;38(4):525–7.CrossRefGoogle Scholar
  6. 6.
    Sobin LH, Fleming ID. TNM Classification of Malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803–4.CrossRefGoogle Scholar
  7. 7.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Blackwell Publishing Ltd; 2010.Google Scholar
  8. 8.
    Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefGoogle Scholar
  9. 9.
    Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22(14):2767–73.CrossRefGoogle Scholar
  10. 10.
    Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.CrossRefGoogle Scholar
  11. 11.
    Wittekind CH, Compton CC, Brierley J, Sobin LH. The TNM clinical and pathological classifications. In: TNM supplement. A commentary on uniform use. Oxford: Wiley-Blackwell; 2012. p. 7.Google Scholar
  12. 12.
    Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.CrossRefGoogle Scholar
  13. 13.
    Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.CrossRefGoogle Scholar
  14. 14.
    Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.CrossRefGoogle Scholar
  15. 15.
    Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11(2):127–39.CrossRefGoogle Scholar
  16. 16.
    Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82(3):346–51.CrossRefGoogle Scholar
  17. 17.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRefGoogle Scholar
  18. 18.
    Sue-Ling HM, Johnston D, Martin IG, et al. Gastric cancer: a curable disease in Britain. Br Med J. 1993;307:591–6.CrossRefGoogle Scholar
  19. 19.
    Degiuli M, Sasako M, Ponti A, et al. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.CrossRefGoogle Scholar
  20. 20.
    Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefGoogle Scholar
  21. 21.
    Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.CrossRefGoogle Scholar
  22. 22.
    Griffith JP, Sue-Ling HM, Martin I, Dixon MF, McMahon MJ, Axon AT, et al. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 1995;36(5):684–90.CrossRefGoogle Scholar
  23. 23.
    Wanebo HJ, Kennedy BJ, Winchester DP, Stewart AK, Fremgen AM. Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on long term survival. J Am Coll Surg. 1997;185(2):177–84.CrossRefGoogle Scholar
  24. 24.
    Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002;131(4):401–7.CrossRefGoogle Scholar
  25. 25.
    Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93(5):559–63.CrossRefGoogle Scholar
  26. 26.
    Toge T, Kameda A, Kuroi K, Seto Y, Yamada H, Hattori T. The role of the spleen in immunosuppression and the effects of splenectomy on prognosis in gastric cancer patients. Nihon Geka Gakkai Zasshi. 1985;86(9):1120–3.PubMedGoogle Scholar
  27. 27.
    Yang K, Chen XZ, Hu JK, et al. Effectiveness and safety of splenectomy for gastric carcinoma: a meta-analysis. World J Gastroenterol. 2009;15:5352–9.CrossRefGoogle Scholar
  28. 28.
    Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in Total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277–83.CrossRefGoogle Scholar
  29. 29.
    Kitamura M, Arai K, Iwasaki Y. Clinicopathological studies and problems on para-aortic lymph node dissection: D4 dissection. Nippon Geka Gakkai Zasshi. 1996;97:302–7.PubMedGoogle Scholar
  30. 30.
    Isozaki H, Okajima K, Fujii K, et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepato-Gastroenterology. 1999;46:549–54.PubMedGoogle Scholar
  31. 31.
    Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.CrossRefGoogle Scholar
  32. 32.
    Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015–22.CrossRefGoogle Scholar
  33. 33.
    Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.CrossRefGoogle Scholar
  34. 34.
    Ito S, Sano T, Mizusawa J, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20(2):322–31.CrossRefGoogle Scholar
  35. 35.
    Nishi M, Kaji S, Akune T, et al. Cardia cancer: a proposal of esophagogastric junction cancer. Geka Shinryo. 1973;15:1328–38. (in Japanese)Google Scholar
  36. 36.
    Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction—classification, pathology and extent of resection. Dis Esophagus. 1996;9:173–82.CrossRefGoogle Scholar
  37. 37.
    Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer. 2013;16(3):301–8.CrossRefGoogle Scholar
  38. 38.
    Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100(2):261–6.CrossRefGoogle Scholar
  39. 39.
    Yamashita H, Seto Y, Sano T, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(Supple 1):S69–83.CrossRefGoogle Scholar
  40. 40.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRefGoogle Scholar
  41. 41.
    Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Inoue H, Yamada K, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol. 2009;16(5):1241–6.CrossRefGoogle Scholar
  42. 42.
    Kakeji Y, Korenaga D, Baba H, Watanabe A, Tsujitani S, Maehara Y, et al. Surgical treatment of patients with gastric carcinoma and duodenal invasion. J Surg Oncol. 1995;59(4):215–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Gastroenterological Surgery, Cancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations